Merck & Co., Inc. MRK
At closeNov 11, 2026, 9:12 AM EST
Pre-market · Nov 11, 9:12 AM ET
- YTD
- +40.65%
- 1 year
- +62.78%
- Market cap
- 364.98B
- Revenue (ttm)
- 67.38B
- Profit margin
- 3.64%
- EPS (ttm)
- 0.99
- Shares out
- 2.47B
- P/E ratio
- 149.54
- Forward P/E
- 16.48
- Dividend
- 3.40 (2.26%)
- Ex-dividend date
- Sep 14, 2026
- YTD return
- +40.65%
- 1-year return
- +62.78%
- Volume
- 5.36M
- Avg volume
- 10.38M
- Open
- 148.40
- Previous close
- 148.05
- Day's range
- 145.58 – 149.19
- 52-week range
- 90.90 – 156.92
- Beta
- 0.12
- Analysts
- Buy
- Price target
- 161.53 (+9.1%)
- Earnings date
- Feb 2, 2027
5D +0.32 (+0.22%)
Key statistics
- Enterprise value
- 411.04B
- PEG ratio
- 3.55
- Price / sales
- 5.42
- Price / book
- 8.13
- Dividend yield
- 2.29%
- Payout ratio
- 343.43%
- Revenue growth
- 4.70%
- Free cash flow
- 14.02B
- Total cash
- 9.65B
- Total debt
- 53.90B
- Return on equity
- 5.06%
- Short % of float
- 1.09%
- 50-day average
- 146.37
- 200-day average
- 127.85
Analyst view
Consensus: buy
- Target (low)
- 105.00
- Target (mean)
- 161.53
- Target (high)
- 186.00
- Strong buy5
- Buy14
- Hold9
- Sell0
- Strong sell0
Next earnings
Feb 2, 2027
Expected Feb 2, 2027. Consensus EPS estimate 1.76.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 2, 2027 | Dec 30, 2026 | 1.78 | — | — | — |
| Oct 29, 2026 | Sep 30, 2026 | 2.09 | 2.49 | +0.40 | +19.14% |
| Aug 4, 2026 | Jun 30, 2026 | -0.27049 | -0.13 | +0.14 | +51.94% |
| Apr 30, 2026 | Mar 31, 2026 | -1.47 | -1.28 | +0.19 | +12.93% |
| Feb 3, 2026 | Dec 31, 2025 | 2.01 | 2.04 | +0.03 | +1.49% |
| Oct 30, 2025 | Sep 30, 2025 | 2.36 | 2.58 | +0.22 | +9.32% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 2, 2026 | Freedom Broker | main | Hold | Hold |
| Nov 2, 2026 | Cantor Fitzgerald | main | Neutral | Neutral |
| Oct 30, 2026 | JP Morgan | main | Overweight | Overweight |
| Oct 30, 2026 | RBC Capital | main | Sector Perform | Sector Perform |
| Oct 30, 2026 | Guggenheim | main | Buy | Buy |
| Oct 26, 2026 | Barclays | main | Overweight | Overweight |
About Merck & Co., Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- United States
- Website
- merck.com
News
FDA Approves PIMJETMI® (pimicotinib) for Patients with Tenosynovial Giant Cell Tumor 
Merck Announces Positive Results from Phase 2b Trial of Efinopegdutide in Adults with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Stage 2-3 Fibrosis 
Merck Reports Phase 2b Results For Efinopegdutide In MASH, Meaningful Improvements Were Observed In Liver Fibrosis Without Worsening Of Steatohepatitis, A Key Secondary Histologic Endpoint; Results Presented At The Liver Meeting And Published In The Lancet 
Merck Announces Positive Results from Phase 2b Trial of Efinopegdutide in Adults with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Stage 2-3 Fibrosis 
INVA or MRK: Which Is the Better Value Stock Right Now? 
11 Of 11 Sectors Rise Monday As Growth Leads 
MRK's 2027 Outlook Challenging, Long-Term Prospects Promising 
Two 70-Year-Olds Will Start the Same $12,272 Keytruda Qlex Cancer Injections. One With Medigap Plan G Will Owe $0 in Coinsurance After the Part B Deductible, While the Other Will Owe 20% With No Annual Cap 
Merck & Co., Inc. $MRK Stock Purchased by Asset One Wealth Management LLC 
Merck Stock Shows Sustained Strength: Time to Buy, Sell or Hold?
Your note
Sign in to keep a note on MRK — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHATTOPADHYAY SANAT | Officer | Conversion of Exercise of derivative security | Apr 28, 2026 | 200,675 |
| DAVIS ROBERT M | Chief Executive Officer | Conversion of Exercise of derivative security | Apr 28, 2026 | 450,351 |
| DELUCA RICHARD ROBERT JR. | Officer | Sale | Aug 11, 2026 | 110,167 |
| GUINDO CHIRFI | Officer | Sale | Aug 12, 2026 | 36,613 |
| LI DEAN Y | Officer | Conversion of Exercise of derivative security | Apr 28, 2026 | 94,431 |
| LITCHFIELD CAROLINE | Chief Financial Officer | Conversion of Exercise of derivative security | Apr 28, 2026 | 92,300 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 9.21% | 226,999,837 | 33.61B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 6.54% | 161,323,174 | 23.88B | Jun 29, 2026 |
| State Street Corporation | 4.88% | 120,413,256 | 17.83B | Jun 29, 2026 |
| Wellington Management Group, LLP | 3.50% | 86,249,283 | 12.77B | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 2.75% | 67,738,969 | 10.03B | Jun 29, 2026 |
| Geode Capital Management, LLC | 2.50% | 61,565,702 | 9.11B | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.18% | 78,411,374 | 11.61B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.60% | 63,996,884 | 9.47B | Jun 29, 2026 |
| SCHWAB STRATEGIC TRUST-Schwab US Dividend Equity ETF | 1.47% | 36,188,606 | 5.36B | Aug 30, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.33% | 32,874,367 | 4.87B | Sep 29, 2026 |
| Fidelity Concord Street Trust-Fidelity 500 Index Fund | 1.30% | 32,063,279 | 4.75B | Sep 29, 2026 |
| SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust | 1.24% | 30,514,312 | 4.52B | Sep 29, 2026 |